Image pharmaphorum Editor Patients Why real patient centricity is more essential than ever befo... Ask nearly any pharma company these days if they’re patient-centric, and you’ll probably get an answer in the affirmative. Views & Analysis Why blockchain is big pharma’s big focus To address the supply chain vulnerabilities of the pharma industry, an innovative, collaborative blockchain-based system could help to keep track of drugs in transit and ensure they are sto Views & Analysis How pharma can thrive in the digital era December marks the one year anniversary of the U.S. Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa Load more results
Patients Why real patient centricity is more essential than ever befo... Ask nearly any pharma company these days if they’re patient-centric, and you’ll probably get an answer in the affirmative.
Views & Analysis Why blockchain is big pharma’s big focus To address the supply chain vulnerabilities of the pharma industry, an innovative, collaborative blockchain-based system could help to keep track of drugs in transit and ensure they are sto
Views & Analysis How pharma can thrive in the digital era December marks the one year anniversary of the U.S.
Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.